SAB Biotherapeutics (SABS) Stock Statistics & Valuation Metrics

SAB Biotherapeutics has a market cap or net worth of $192.59M. The enterprise value is $31.58M.

SAB Biotherapeutics has 50,951,040 shares outstanding. The number of shares has decreased by -2.65% in one year.

SAB Biotherapeutics’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is -30.02%.

The current PE Ratio of SAB Biotherapeutics is 5.4. SAB Biotherapeutics’s PEG ratio is -0.05.

In the last 12 months, SAB Biotherapeutics had revenue of 0.00 and earned 13.27M in profits. Earnings per share was 0.22.

In the last 12 months, operating cash flow was -44.78M and capital expenditures -933.15K, giving a free cash flow of -45.71M billion.

SAB Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

SAB Biotherapeutics upcoming earnings date is May 8, 2026, During Market Hours (Confirmed).

SAB Biotherapeutics as a current ratio of 9.46, with Debt / Equity ratio of 3.93%

In the past 12 months, SAB Biotherapeutics has paid 0.00 in taxes.

SAB Biotherapeutics EV to EBITDA ratio is 4.08, with an EV/FCF ratio of -1.48.

SAB Biotherapeutics has $96.59M in cash and marketable securities with $5.95M in debt, giving a net cash position of $90.64M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for SAB Biotherapeutics is $10.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy